

# PRODUCT INFORMATION

## Azilsartan DCHA Salt

Innovative Antihypertensive API with Enhanced Solubility, Stability, and Bioavailability

### 1. Improved Solubility

- Exhibits higher solubility in pH 6.8 buffer and aqueous media compared with Azilsartan medoxomil potassium salt.
- Enhanced dissolution facilitates better absorption in physiological conditions.

### 2. Enhanced Bioavailability

- In rat oral studies, C<sub>max</sub> and AUC values were higher than those of Azilsartan medoxomil potassium salt.
- Demonstrated approximately 30% increase in bioavailability, providing superior systemic exposure.

### 3. Superior Stability

- Shows remarkable stability improvement under both room temperature and 65 °C conditions compared with Azilsartan.
- Enhanced solid-state stability contributes to better shelf-life and formulation robustness.

### 4. Development Status

Item	Status
Japanese Patent	JP7638551 (Registered: Feb 21, 2025)
Pharmacokinetic Study	Completed (Beagle dogs)
Efficacy (pre-clinical)	Ongoing (SHR model)

### Conclusion

Azilsartan DCHA Salt represents a next-generation form of Azilsartan with improved solubility, bioavailability, and stability. It offers formulation scientists a superior option for developing more effective and stable antihypertensive therapies.